Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

China SXT Pharmaceuticals (SXTC) Equity Average: 2018-2025

Historic Equity Average for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $14.7 million.

  • China SXT Pharmaceuticals' Equity Average rose 23.16% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.8 million, marking a year-over-year increase of 23.16%. This contributed to the annual value of $14.7 million for FY2025, which is 2.62% up from last year.
  • China SXT Pharmaceuticals' Equity Average amounted to $14.7 million in FY2025, which was up 2.62% from $14.3 million recorded in FY2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Equity Average peaked at $16.2 million during FY2022, and registered a low of $12.7 million during FY2021.
  • For the 3-year period, China SXT Pharmaceuticals' Equity Average averaged around $14.9 million, with its median value being $14.7 million (2025).
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Equity Average grew by 27.69% in 2022, and later declined by 8.02% in 2024.
  • China SXT Pharmaceuticals' Equity Average (Yearly) stood at $12.7 million in 2021, then climbed by 27.69% to $16.2 million in 2022, then declined by 3.92% to $15.6 million in 2023, then dropped by 8.02% to $14.3 million in 2024, then grew by 2.62% to $14.7 million in 2025.